Universität zu Köln

Gruell, Henning and Schommers, Philipp ORCID: 0000-0003-3375-6800 (2022). Broadly neutralizing antibodies against HIV-1 and concepts for application. Curr. Opin. Virol., 54. OXFORD: ELSEVIER SCI LTD. ISSN 1879-6265

Full text not available from this repository.

Abstract

Potent broadly neutralizing antibodies (bNAbs) targeting HIV-1 exhibit significant antiviral activity in humans. Recent advances have demonstrated that novel antibodies and bNAb combinations can effectively restrict the development of viral escape mutations. Moreover, passive immunization trials have provided proof-of-principle for bNAb-mediated prevention of infection with antibody-sensitive HIV-1 strains. In contrast, clinical studies investigating the activity of HIV-1 bNAbs on the latent reservoir failed to demonstrate substantial effects. Clinical adoption of HIV-1 bNAbs will require the development of more potent and broadly active antibodies as well as their implementation in optimized strategies to fully harness the capabilities of bNAbs. We review preclinical and clinical studies on HIV-1 bNAbs to highlight their potential and remaining limitations.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gruell, Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Schommers, Philipp UNSPECIFIED orcid.org/0000-0003-3375-6800 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-661531
DOI:	10.1016/j.coviro.2022.101211
Journal or Publication Title:	Curr. Opin. Virol.
Volume:	54
Date:	2022
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1879-6265
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SILENT FACE; THERAPY; RESPONSES Multiple languages Virology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66153